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A B S T R A C T
The ketogenic diet has been used for the treatment of epilepsy in childhood for almost 100 years.
Although initial use was wide, the advent of antiepileptic drugs led to reduced utilisation. However, an
apparently ‘forgotten treatment’ gained further popularity in the early 1990s when signiﬁcant
individuals gained beneﬁt. This aside, although there aremany open label trials to suggest beneﬁt can be
gained in children with drug resistant epilepsy it is only recently that deﬁnitive evidence from
randomised controlled trials has become available. There continues to be a constant struggle with the
demand for the resources required, and therefore availability and apparent management choice is
limited.
 2010 Published by Elsevier Ltd on behalf of British Epilepsy Association.
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Dietary therapies are often perceived as natural treatments for
disease. Certainly prior to the advent of medication, in particular
antiepileptic drugmedication, alternative forms of treatment were
sought for treatment of the epilepsies. The earliest reports of the
effects of starvation on epilepsy date back to the ﬁfth centurywhen
Hippocrates described a man whose seizures were cured by
abstaining from all food and drink. However subsequent ﬁrst
reports in the medical literature were by Guelpa and Marie who
described the effect of complete fasting on the cessation of
seizures.1 This was also subsequently reported again in 1921 by
Geyelin, reporting that 20 out of 26 fasted patients had improved
seizure control, 2 of whom remained seizure free for more than a
year.2 This work had been inspired by the work of an osteopath,
Conklin, who believed that epilepsy was caused by intoxication
from the payers patches of the intestine and therefore advocated
complete rest of the gut3. He fasted his patients for up to 25 days,
reporting a 90% success rate in children under the age of 10 years,
decreasing with age to 50% in adults. Such observations lead to
considerable clinical and research interest and debate as to
whether a similar metabolic state in the body to starvation could
be obtained by other means.
It was suggested by Wilder that a diet high in fat and low in
carbohydrate may mimic the ketotic effect; driving the body to
utilise the fat in the diet, so generating ketosis.4 Subsequent work
showed that 50% of Wilder’s patients at The Mayo Clinic had
signiﬁcant seizure control using this method. Peterman subse-
quently also reported further successful results in 37 patients with
95% showing improvement when treated by the diet.5 Subse-E-mail address: hcross@ich.ucl.ac.uk.
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other workers and it was widely used up until the 1950s, probably
coming out of favour in the late 1930s with the introduction of
phenytoin and a presumption that an antiepileptic drug was likely
to preclude any use for a change in the diet. Over the years it was
used to a limited degree but there was great concern about the
possible side effects and the burden on families of children trialled
on the diet.
The diet used was the classical form based on a ratio of fat to
carbohydrate in the diet of 3 or 4:1. There was concern about
abdominal side effects and the possible long-term side con-
sequences such a diet may have on a child. Despite it being a
dietary treatment it could not be thought of as a natural treatment
and of course did provide dietary restrictions. There was also little
in the way of scientiﬁc study to determine whether it was more
beneﬁcial than any other routine treatment in the effects on
seizures. In 1971 a further modiﬁcation of the classical diet was
suggested in an attempt to lead to a greater palatability and less in
the way of side effects. Huttenlocher reported the use of medium
chain triglycerides (MCT) as an alternative fat choice, medium
chain triglyceride beingmore ketogenic per calorie than long chain
fat.6 The main constituents of MCT are the medium chain length
octanoic and decanoic fatty acids absorbed more efﬁciently than
their long-term counterparts, being carried more directly to the
liver in the portal blood. Following hepatic tissue uptake there are
also further differences, long chain fat is ﬁrstly bound to carnitine,
required to transport such across the mitochondrial membrane
where beta oxidation and keto body synthesis occurs. Such a
carnitine shuttle system is not required for medium chain fatty
acids, which enter mitochondria directly. This more rapid and
greater oxidation of medium chain fatty acids than their long chain
counterparts results in a higher ketone production per kilocalorie
of energy. Such an increase in ketogenic potential meant that lessEpilepsy Association.
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supposedly more generous in protein and carbohydrate. Hutten-
locher later showed that the ketogenic diet provided in this way
was as effective as a 3:1 classical diet in producing ketosis and
controlling seizures in a small number of children.7 However there
remained concern about efﬁcacy and, indeed, tolerability. In view
of concerns about side effects, Schwartz and colleagues developed
a modiﬁed MCT diet using both MCT and long chain fat, providing
only 30% of energy from MCT oil and an extra 30% from saturated
fats (as compared to 60%MCT in theMCT diet). This became known
as The John Radcliffe Diet.8
Prior to the early 1990s there continued to be limited use of the
ketogenic diet and a certain scepticism with regard to its efﬁcacy.
Renewed publicity was enhanced by the successful use of the diet
in key individuals, most notably ‘‘Charlie’’ the son of Jim Abrahams,
a ﬁlm producer. There was consequently increased advocacy for its
use, with development of ‘‘The Charlie Foundation’’ in the USA, and
the production of the ﬁlm ‘‘Do no harm’’ starring Meryl Streep
telling their story.
2. Evidence base for the use of the ketogenic diet
There was much in the way of open label data to suggest
efﬁcacy of the ketogenic diet in the treatment of epilepsy; a
systematic review published in 2000 concluded there was
sufﬁcient evidence to suggest that the diet was efﬁcacious in
childrenwith intractable epilepsy. However it was noted that there
was a lack evidence from controlled trials.9 Only 11 studies were
eligible for review, all 11 were observational, only 2 prospective
and 9 of the 11 studies were from a single institution. This
institution was The John Hopkins Hospital in Baltimore, which had
advocated the diet’s use over many years. A further systematic
review, published in 2006, reviewed 14 studies with the inclusion
criteria that there required to be at least 6 months follow-up
following initiation of the diet.10 This review reached a similar
conclusion with a total collective population of 972 (studies
reviewed since 1990); at 6month followup 15.6% collectivelywere
seizure free and 33% of children had more than a 50% reduction of
seizures. However again it was highlighted that there were no
prospective controlled trials; and this was further emphasised by a
Cochrane review published in 2003, which also failed to ﬁnd any
randomised controlled trial with regard to assessing the efﬁcacy of
the ketogenic diet.11
More recently the ﬁrst randomised controlled trial has been
published with the use of the ketogenic diet in drug resistant
epilepsy in childhood.12 This study randomised 145 children aged
between 2 and 16 years, who had at least daily seizures and failed
to respond to at least 2 antiepileptic drugs. Children in this study
were randomly assigned to receive a ketogenic diet either after a 4-
week baseline period of seizure documentation or after a further 3-
month delay where there was no change in treatment (the control
group). At 3 months data for 103 children were available for
analysis, 54 on the ketogenic diet and 49 controls. Compared to
baseline, there was a 38% reduction in mean seizure frequency for
the diet group and a 37% increase for controls (a mean percentage
difference between the groups of 75%). Twenty-eight children in
the diet group achieved a responder rate of greater than 50%
reduction in seizures compared to only 4 controls, a difference
which reached signiﬁcance. A further aim of this study was to
determine whether there was any difference in efﬁcacy between
the classical and the MCT diets. At no time point, namely 3, 6 or 12
months was there any signiﬁcant difference in efﬁcacy, either in
the percentage of baseline seizures or in responder rates.13
There has been another randomised control study published
since this time, also a double blind study involving children with
Lennox–Gastaut Syndrome.14 Children were initially fasted andsubsequently clinical and EEG events were documented. All
children in the study received a ketogenic diet, but 50% of them
received a saccharin drink and 50% a glucose drink, those with the
latter assumed to break ketosis. Children were unaware, as were
parents, which of the diets they were receiving. They were all in-
patients, seizure frequency was documented and EEG was
performed prior to the start of the dietary treatment. At 6 days
children were reassessed and subsequently crossed over to receive
the alternative drink. Seizure count and EEG data were recorded at
this point and again after a further 6 days. No signiﬁcant difference
in electrical or clinical events were noted between the ketogenic
diet and the non-ketogenic diet (glucose drink) periods, but the
methodology may have precluded ultimate signiﬁcance. The
baseline seizure frequencies were documented after a 24-h period
of fasting and subsequently children receiving the glucose drink
did not break ketosis and therefore could not be assumed to be on a
normal diet.
Tolerability of the diet has also been a concern and of course it is
necessary for it to be palatable. In the short term the randomised
controlled trial reported conﬁrming data from open label studies
that vomiting, diarrhoea, constipation and hunger were the most
commonly reported side effects, however the majority could be
alleviated by dietary manipulation and therefore very few with-
drawals prior to or at the 3-month period were due to these side
effects.12 Further no signiﬁcant difference was seen between the 2
types of dietwith regard to side effects at 3 or 12months.13 There is
no question the behaviour issues seen around feeding times were a
problem, but behaviour problems per se did not appear to be a
contraindication to the diet. Further, gastro-oesophageal reﬂux
may be exacerbated by a high fat diet in view of the delayed gastric
emptying and needs to be considered prior to initiation. Children
do appear to bruise more easily and therefore require careful
monitoring in view of inaccurate conclusions that may be drawn
with the occurrence of spontaneous bruising.15 This is likely to be
due to prolonged bleeding times and platelet aggregation
abnormalities, but these do not preclude safety during surgical
procedures.16 Raised blood cholesterol is also seen on all children
but raised blood triglycerides do not occur on the MCT diet. The
exact long-term implications of this remain unclear.
Long-term a main concern has been that of the occurrence of
renal stones, children who are non-ambulant and the very young
with a high calcium excretion being those who are most at risk.17
Additionally, growth may be impaired.18,19 There appears to be
negative change in the Z score, that is deviation of the height
velocity away from the normal trajectory, the longer the duration
of the diet, particularly noticeable in the very young. At each stage
the risk beneﬁt ratio with regard to a child remaining on the diet
needs to be assessed.
3. In whom is it suitable?
As outlined above, the ketogenic diet cannot be considered to be
a ‘natural treatment’. It can have side effects like many of the
anticonvulsant medications. Further it requires a high degree of
dietary supervision, and for the children only to eat according to
the prescription. Although a varied menu can be provided within
the requirements, it is still restrictive to some degree on lifestyle.
For these reasons, it should be considered only in drug resistant
epilepsy as a possible management option after failure of at least
two AEDS. Syndrome speciﬁc efﬁcacy has been suggested in Doose
syndrome,20 Dravet syndrome21 and West syndrome 22; in these
syndromes the diet may therefore be considered earlier in
management rather than later. However, there are certain
metabolic conditions with epilepsy as a symptom for which the
diet would be the treatment of choice. These are conditions where
the individual is unable to use glucose as the primary fuel, and
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defects, pyruvate dehydrogenase deﬁciency. An understanding of
these conditions has led to the suggestion that glucose transporter
defects may be responsible for a wider range of epilepsies, and
therefore that the ketogenic diet be a suitable treatment for a larger
population.23 Likewise the diet will be contraindicated in children
with metabolic conditions where they are unable to utilise
ketones, and require glucose e.g. pyruvate decarboxylase deﬁcien-
cy and fatty acid oxidation defects.24
4. Alternative diets
The ketogenic diet either in the classical or the MCT form
remains restrictive and prescriptive. It requires careful monitoring
by a dietician, particularlywith its use in children. Use in adults has
been attempted, but in view of its restrictions has been extremely
difﬁcult and it has been noted that even where beneﬁt is seen,
adults are not able to continue with the ketogenic diet in the
immediate term.25 Considering this, alternativeways of generating
ketosis and therefore administering the diet have been considered.
A modiﬁed Atkins Diet is very similar to the ketogenic diet with
high fat and low carbohydrate but there remains unlimited protein
within the diet therefore allowing more in the way of palatability.
In a limited open label study in adults aged 18–50 years of age, 10
discontinued the diet before 3 months, but 40% had more than a
50% reduction of seizures at this time.26 A larger study of children
in Korea showed a similar efﬁcacy and similar retention rates.27
Certainly this is a less restrictive diet thatmay have a role to play in
teenagers and adults. An alternative way of generating ketosis has
been suggested using a low glycaemic diet. The glycaemic index is
calculated from the incremental area under the blood glucose
curve after feeding, more complex sugars therefore not leading to a
rapid rise in blood sugar. In a series of children reported in an open
label fashion in Boston, 50% were demonstrated to have more than
a 50% of reduction of seizures at 3 months.28 The authors suggest
this approach could be trialled in the ﬁrst instance and if some
beneﬁt were demonstrated, the ketogenic diet could be used
subsequently. This is a diet that could also be trialled in older
individuals, to allow greater palatability.
5. How does it work – will we ever be able to use ‘a pill’
Research through basic science has attempted to determine the
possible anitepileptogenic (and potentially neuroprotective)
effects of the diet.29,30 Many systemic and metabolic changes
are induced once a child initiates the diet, but as with many of the
antiepileptic medications, which effects determined in vitro
remain the most relevant in vivo is unclear. Early study suggested
that seizure reduction was related to the degree of ketosis; the
relationship is not direct however and although acetone has been
shown to prevent acutely provoked seizures in animals there is no
evidence that ketone bodies can have a direct effect on synaptic
transmission or neuronal excitability. Experimental data have also
suggested the diet may increase mitochondrial biogenesis and
energy metabolism, or a possible role for polyunsaturated fatty
acids adminstered as part of the diet.29 It is likely that the
underlying changes induced by the ketogenic diet responsible for
the antiepileptic effect are multiple and synergistic,31 and
therefore it appears unlikely that in the immediate future, the
diet will be replaced by a simple medication or pill alone.
6. Current position on the use of the ketogenic diet in epilepsy
Key to the implementation of the ketogenic diet is the
availability of a skilled dietician as part of a ketogenic diet team,
to ensure dietary and calorie intake appropriate to the age andmedical condition of the child. The diet must be nutritionally
adequate with vitamin, mineral and tracer element supplementa-
tion where required. There is a general consensus that the
ketogenic diet or equivalent should be available as part of any
epilepsy service, and in certain epilepsy syndromes offered earlier
rather than later.24 Evidence is now in favour of initiation
appropriate to service availability; outpatient intiation without
fasting is currently considered appropriate where adequate
support is available. However, despite the increasing evidence of
efﬁcacy, and increasing awareness amongst families, there still
remains lack of choice for either a family or professional team
owing to lack of resources required. Timing of the offer of a
ketogenic diet continues to be driven by waiting lists, and referral
patterns skewed by availability.32 It is generally accepted that such
a service continues to require provision through a paediatric
neurology service until wider experience is achieved. One
approach has been for charitable organisations to support services
in some way, not least by funding of dieticians at least in the short
term. Further, such organisations can provide additional support in
tandem with professional services. Speciﬁc funding streams for
provision of such services however do need to be determined.
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